Validation of novel identification algorithms for major adverse cardiovascular events in a Japanese claims database

被引:13
|
作者
Shima, Daisuke [1 ]
Ii, Yoichi [2 ]
Higa, Shingo [1 ]
Kohro, Takahide [3 ]
Hoshide, Satoshi [4 ]
Kono, Ken [4 ]
Fujimoto, Shigeru [5 ]
Niijima, Satoshi [4 ]
Tomitani, Naoko [4 ]
Kario, Kazuomi [4 ]
机构
[1] Pfizer Japan Inc, Tokyo, Japan
[2] Pfizer R&D Japan GK, Tokyo, Japan
[3] Jichi Med Univ, Dept Clin Informat, Sch Med, Shimotsuke, Tochigi, Japan
[4] Jichi Med Univ, Dept Med, Sch Med, Div Cardiovasc Med, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan
[5] Jichi Med Univ, Dept Med, Sch Med, Div Neurol, Shimotsuke, Tochigi, Japan
来源
JOURNAL OF CLINICAL HYPERTENSION | 2021年 / 23卷 / 03期
关键词
algorithms; health administrative data; myocardial infarction; stroke; validation study; ACUTE MYOCARDIAL-INFARCTION; HEALTH-CARE PROFESSIONALS; DEFINITION; ACCURACY; STROKE;
D O I
10.1111/jch.14151
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Predicting clinical outcomes can be difficult, particularly for life-threatening events with a low incidence that require numerous clinical cases. Our aim was to develop and validate novel algorithms to identify major adverse cardiovascular events (MACEs) from claims databases. We developed algorithms based on the data available in the claims database International Classification of Diseases, Tenth Revision (ICD-10), drug prescriptions, and medical procedures. We also employed data from the claims database of Jichi Medical University Hospital, Japan, for the period between October 2012 and September 2014. In total, we randomly extracted 100 potential acute myocardial infarction cases and 200 potential stroke cases (ischemic and hemorrhagic stroke were analyzed separately) based on ICD-10 diagnosis. An independent committee reviewed the corresponding clinical data to provide definitive diagnoses for the extracted cases. We then assessed the algorithms' accuracy using positive predictive values (PPVs) and apparent sensitivities. The PPVs of acute myocardial infarction, ischemic stroke, and hemorrhagic stroke were low only by diagnosis (81.6% [95% CI 72.5-88.7]; 31.0% [95% CI 22.8-40.3]; and 45.5% [95% CI 34.1-57.2], respectively); however, the PPVs were elevated after adding the prescription and procedure data (87.0% [95% CI 78.3-93.1]; 44.4% [95% CI 32.7-56.6]; and 46.1% [95% CI 34.5-57.9], respectively). When we added event-specific prescription and procedure data to the algorithms, the PPVs for each event increased to 70%-98%, with apparent sensitivities exceeding 50%. Algorithms that rely on ICD-10 diagnosis in combination with data on specific drugs and medical procedures appear to be valid for identifying MACEs in Japanese claims databases.
引用
收藏
页码:646 / 655
页数:10
相关论文
共 50 条
  • [1] Validation of Major Adverse Cardiovascular Events (MACE) in US Claims Databases
    Haynes, Kevin
    Nezamzadeh, Melissa S.
    Newcomb, Craig W.
    Roy, Jason
    Kite, Whitney
    Carbonari, Dena M.
    Cardillo, Serena
    Hennessy, Sean
    Freeman, Cristin P.
    Holick, Crystal N.
    Esposito, Daina B.
    Strom, Brian L.
    Vincent, Lo Re
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 394 - 395
  • [2] Prevalence and prediction of major adverse cardiovascular events after liver transplantation using a novel database
    VanWagner, Lisa B.
    Serper, Marina
    Kang, Raymond
    Skaro, Anton I.
    Levitsky, Josh
    Hohmann, Samuel
    Lloyd-Jones, Donald M.
    [J]. HEPATOLOGY, 2014, 60 : 450A - 451A
  • [3] Validation of an Australian claims database to detect adverse events post drug therapy
    Pratt, Nicole
    Roughead, Elizabeth
    Peck, Robert
    Gilbert, Andrew
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S195 - S195
  • [4] Machine learning algorithms to predict major adverse cardiovascular events in patients with diabetes
    Abegaz, Tadesse M.
    Baljoon, Ahmead
    Kilanko, Oluwaseun
    Sherbeny, Fatimah
    Ali, Askal Ayalew
    [J]. COMPUTERS IN BIOLOGY AND MEDICINE, 2023, 164
  • [5] The identification of three novel biomarkers of major adverse kidney events
    Haase, Michael
    Bellomo, Rinaldo
    Albert, Christian
    Vanpoucke, Gregoire
    Thomas, Griet
    Laroy, Wouter
    Verleysen, Katleen
    Kropf, Siegfried
    Kuppe, Hermann
    Hetzer, Roland
    Haase-Fielitz, Anja
    [J]. BIOMARKERS IN MEDICINE, 2014, 8 (10) : 1207 - 1217
  • [6] Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
    Zhao, Hui
    Li, Jun-Min
    Li, Zi-Ran
    Zhang, Qian
    Zhong, Ming-Kang
    Yan, Ming-Ming
    Qiu, Xiao-Yan
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [7] Rises in Hematocrit Are Associated With an Increased Risk of Major Adverse Cardiovascular Events in Men Starting Testosterone Therapy: A Retrospective Cohort Claims Database Analysis
    Kohn, Taylor P.
    Agrawal, Pranjal
    Ory, Jesse
    Hare, Joshua M.
    Ramasamy, Ranjith
    [J]. JOURNAL OF UROLOGY, 2024, 211 (02): : 285 - 293
  • [8] Impact of medical checkup parameters on major adverse cardiovascular events in the general Japanese population
    Sugiura, Tomonori
    Takase, Hiroyuki
    Dohi, Yasuaki
    Yamashita, Sumiyo
    Seo, Yoshihiro
    [J]. PREVENTIVE MEDICINE REPORTS, 2024, 38
  • [9] Prediabetes and the Incidence of Major Adverse Cardiovascular Events
    Booth, Gillian L.
    Rezai, Mohammad R.
    Atzema, Clare
    Austin, Peter C.
    Bhatia, Sacha
    Bierman, Arlene S.
    Clemens, Kristin K.
    Johnston, Sharon
    Ko, Dennis T.
    Lee, Douglas S.
    Tu, Karen
    Tu, Jack V.
    [J]. DIABETES, 2017, 66 : A81 - A82
  • [10] Triglyceride-Glucose Index as a Novel Biomarker for Major Adverse Cardiovascular Events
    Zhang, Xin
    Yang, Yong
    Jiang, Yun-Shan
    [J]. ANGIOLOGY, 2024,